Novo Nordisk's Wegovy weight loss drug approved in China

Novo Nordisk announced that its Wegovy weight loss treatment has received approval in China for long-term weight management. This approval allows the sale of the drug to individuals with obesity and at least one weight-related comorbidity. China has a significant issue with overweight and obesity, with more than half of its population affected. The drug, which is administered weekly through injections, will initially be available to patients with a body mass index (BMI) of 30kg/m2 or higher. Novo Nordisk has not provided details about pricing or the timeline for the drug’s rollout. The approval comes amidst competition from domestic drug makers and the impending expiration of the drug’s patent in 2026.